Treatment of Asymptomatic Toxocariasis With Albendazole in Children
NCT ID: NCT00755560
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
45 participants
INTERVENTIONAL
2008-09-30
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of Albendazole Treatment Among Infected Toxocara Children
NCT05208333
A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children
NCT01087099
Albendazole Dose Finding and Pharmacokinetics in Children and Adults
NCT03527745
Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2
NCT01379326
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora
NCT01192802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Albendazole
Albendazole 10 - 15 mg/kg/day BID for 15 days
Albendazole
Albendazole 10 - 15 mg/kg/day BID for 15 days
Placebo
Placebo BID for 15 days
Placebo
Placebo BID for 15 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Albendazole
Albendazole 10 - 15 mg/kg/day BID for 15 days
Placebo
Placebo BID for 15 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children 2 - 15 years old
* Absolute eosinophil count \> 1100 / mm3
* Normal ophthalmoscopy
Exclusion Criteria
* Infection by other nematodes (Ascaris lumbricoides, strongyloides stercoralis, uncinarias, Trichuris trichuria)
* Symptomatic patients (prolonged fever, acute pneumonitis, hepatomegaly, splenomegaly, ocular compromise due to toxocara)
* Concomitant diseases
* Immunocompromised patients
* Altered liver or kidney function
* Pregnancy
2 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital de Niños R. Gutierrez de Buenos Aires
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Jaime Altcheh
Service Head, Parasitology and Chagas Service
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaime Altcheh, MD
Role: STUDY_CHAIR
Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
Hector Freilij, MD
Role: PRINCIPAL_INVESTIGATOR
Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires
Buenos Aires, , Argentina
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOXOCARA-ALBENDAZOLE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.